The rise in cancer prevention in developed nations and governments' conscious efforts to promote early diagnosis and treatment have boosted the global market for biosimilar G-CSF sales. The market will experience significant growth as a result of the approved biosimilars Grafeel, Colstim, Neukine, and Filcad, which are also affordable and easily accessible in developing nations. The number of cancer patients is rising in China and India, which is likely to expand the global market. Therefore, using biosimilars rather than the original biologics helps patients pay less for healthcare, which raises demand in the global G-CSF biosimilars sales market. The prices of individual biosimilars are higher than those of generic drugs because of the intricate biological manufacturing processes used to create them.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-g-csf-peg-g-csf-market
Data Bridge Market Research analyses that the G-CSF PEG-G-CSF Market is expected to reach the value of USD 5,685.40 million by 2030, from USD 3,736.34 million in 2022 at a CAGR of 5.5% during the forecast period from 2023 to 2030. Chemotherapy often leads to a decline in white blood cell count, resulting in neutropenia. G-CSF and PEG-G-CSF are commonly used to stimulate the production of neutrophils and reduce the risk of infections in cancer patients undergoing chemotherapy. As the incidence of cancer continues to rise globally, the demand for G-CSF and PEG-G-CSF is expected to increase.
Key Findings of the Study
Increasing incidence of neutropenia is expected to drive the market's growth rate
The increasing incidence of neutropenia, a condition marked by low neutrophil levels, is a significant driver for the G-CSF (Granulocyte Colony-Stimulating Factor) and PEG-G-CSF (Pegylated Granulocyte Colony-Stimulating Factor) market. Neutropenia commonly occurs as a side effect of chemotherapy and certain diseases, necessitating treatments to stimulate the production of white blood cells. G-CSF and PEG-G-CSF are used in such cases to enhance the body's ability to produce neutrophils, leading to a higher demand for these medications.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency, and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcutaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
USV Private Limited (India), Viatris Inc. (U.S.), Biocon (India), Fresenius Kabi AG (Germany), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Apotex Inc. (Canada), Cadila Pharmaceuticals (India), Dr. Reddy’s Laboratories Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.), Coherus BioSciences (U.S.), Accord Healthcare (U.K.), NAPP PHARMACEUTICALS LIMITED. (U.K.), Intas Pharmaceuticals Ltd. (India), Mundipharma International (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Spectrum Pharmaceuticals, Inc. (U.S.), Kyowa Kirin Co., Ltd. (Japan), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The G-CSF PEG-G-CSF market is segmented on the basis of indication, dosage, route of administration, packaging, end user, and distribution channel
- On the basis of indication, the global G-CSF / PEG-G-CSF market is segmented into neutropenia, oncology, chronic and autoimmune disease, blood disorders, growth hormone deficiency and others. In 2023, neutrpenia segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.7% in the forecast period of 2023 to 2030 due to its prevalence in various conditions, including cancer treatments, chemotherapy, and autoimmune diseases. The need for effective treatments to manage low neutrophil levels drives the demand for therapies targeting Neutropenia.
- On the basis of dosage, the global G-CSF / PEG-G-CSF market is segmented into mono and combination. In 2023, the mono segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.3% in the forecast period of 2023 to 2030 due to the maximum number of cancer treatment drugs are comes in mono dosage form only.
In 2023, the mono segment is expected to dominate the dosage segment of the global G-CSF / PEG-G-CSF market
In 2023, the mono segment is expected to dominate the global G-CSF / PEG-G-CSF market owing to the specific condition or symptom. For instance, if a patient is prescribed a mono dosage of a painkiller such as acetaminophen, they would receive a specific amount of acetaminophen without any other active ingredients with a CAGR of 5.3% in the forecast period of 2023 to 2030
- On the basis of route of administration, the global G-CSF / PEG-G-CSF market is segmented into intravenoue, subcutanious and intraperitoneal. In 2023, subcutanious segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.4% in the forecast period of 2023 to 2030 due to the increasing use of subcuetanious injection and self-administration by the patient, shorter time of application process with less infusion related adverse events and consequently lower healthcare costs.
- On the basis of packaging, the global G-CSF / PEG-G-CSF market is segmented into single-use vials and pre filled syringes. In 2023, pre filled syringes segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.4% in the forecast period of 2023 to 2030 due to their convenience, safety, and accuracy in delivering medications. They offer ready-to-use dosages, reduce the risk of contamination, and improve patient compliance, making them preferred choices in healthcare settings.
In 2023, the prefilled syringes segment is expected to dominate the packaging segment of the global G-CSF / PEG-G-CSF market
In 2023, the pre filled syringes segment is expected to dominate the global G-CSF / PEG-G-CSF market owing to their convenience, safety, and accuracy in delivering medications. They offer ready-to-use dosages, reduce the risk of contamination, and improve patient compliance, making them preferred choices in healthcare settings with a CAGR of 5.4% in the forecast period of 2023 to 2030
- On the basis of end user, the global G-CSF / PEG-G-CSF market is segmented into hospitals and clinics, research and academic institute, ambulatory surgical centers and others. In 2023, hospitals and clinics segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.7% in the forecast period of 2023 to 2030 due to Cancer care is complex and requires skilled and accountable leadership and management at all levels so people prefer hospital and clinics.
- On the basis of distribution channel, the global G-CSF / PEG-G-CSF market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. In 2023, the hospital pharmacy segment is expected to dominate the global G-CSF / PEG-G-CSF market with a CAGR of 5.9% in the forecast period of 2023 to 2030 due to greater input in prescribing decisions about drugs and administration and hospital pharmacies are convenient for the patient in emergency.
Major Players
Data Bridge Market Research recognizes the following companies as the major G-CSF PEG-G-CSF market players in G-CSF PEG-G-CSF market are USV Private Limited (India), Viatris Inc. (U.S.), Biocon (India), Fresenius Kabi AG (Germany), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Apotex Inc. (Canada), Cadila Pharmaceuticals (India)
Market Development
- In 2022, The U.S. Food and Drug Administration (FDA) has approved Kashiv Biosciences' Biologics License Application (BLA) for filgrastim-ayow, a biosimilar to Neupogen. The brand name RELEUKO is used to market the product.
- In 2022, Amgen and Generate Biomedicines has announced a research collaboration agreement to discover and develop protein therapeutics for five clinical targets in multiple therapeutic areas and multiple pathways.
- In 2022, Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab.
Regional Analysis
Geographically, the countries covered in the G-CSF PEG-G-CSF market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
Europe is the dominant region in the G-CSF PEG-G-CSF market during the forecast period 2023-2030
Europe's dominance in the G-CSF and PEG-G-CSF market can be attributed to the presence of key market players and the region's largest consumer market with a high GDP. Europe boasts several prominent pharmaceutical companies that have a strong presence in the market. Additionally, the region's significant healthcare infrastructure, favorable reimbursement policies, and emphasis on advanced healthcare technologies contribute to its leadership in the industry, driving market growth and innovation.
North America is estimated to be the fastest-growing region in the G-CSF PEG-G-CSF market for the forecast period 2023-2030
North America is expected to be the fastest growing region for the G-CSF PEG-G-CSF market owing to the United States being expected to experience growth in the G-CSF and PEG-G-CSF market due to its advancements in technology and continuous innovation. The country has a robust healthcare ecosystem, including cutting-edge research facilities, clinical trials, and pharmaceutical companies at the forefront of developing novel therapies. With a focus on advanced healthcare technologies and a strong emphasis on research and development, the U.S. is well-positioned to drive growth in the G-CSF and PEG-G-CSF market through its latest technological advancements and inventions.
For more detailed information about the G-CSF PEG-G-CSF market report, click here – https://www.databridgemarketresearch.com/reports/global-g-csf-peg-g-csf-market
